Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Tobias Kratzsch"'
Autor:
Joshua Alcaniz, Lars Winkler, Mathias Dahlmann, Michael Becker, Andrea Orthmann, Johannes Haybaeck, Stefanie Krassnig, Christina Skofler, Tobias Kratzsch, Susanne A. Kuhn, Andreas Jödicke, Michael Linnebacher, Iduna Fichtner, Wolfgang Walther, Jens Hoffmann
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Glioblastoma (GBM) heterogeneity, aggressiveness and infiltrative growth drastically limit success of current standard of care drugs and efficacy of various new therapeutic approaches. There is a need for new therapies and models reflecting the compl
Externí odkaz:
https://doaj.org/article/162e4abdb64b415cb7d728a8287cc659
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Objective: Spinal metastatic disease remains a major problem of oncological diseases. Patients affected may suffer pain, spinal instability, and severe neurological deficits. Today, palliative surgery and radiotherapy are the mainstays of therapy. In
Externí odkaz:
https://doaj.org/article/39125c90b2214955b5de15adf061f325
Autor:
Uwe Karsten Hanisch, Peter Vajkoczy, Tobias Kratzsch, Susanne Kuhn, Andreas Joedicke, Iduna Fichtner, Jens Hoffmann
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 144:809-819
Glioblastoma multiforme (GBM) is the most lethal primary brain tumor in adults. The epigenetically active ribonucleoside analog 5-azacitidine is a new therapy option that changes tumor cell chromatin, which is frequently modified by methylation and d
Autor:
Tobias Kratzsch
Publikováno v:
Pain Physician. :E831-E840
Background: Intrathecal (IT) drug therapy with implanted pumps is an effective treatment modality for chronic pain and/or spasticity, especially after non-invasive treatment has failed. Long-term use of intrathecal opioids may cause formation of infl
Autor:
Andreas F. Hottinger, Martin N. Stienen, Gerhard Hildebrandt, Susanne Kuhn, Oliver Gautschi, Tobias Kratzsch
Publikováno v:
Praxis. 103:1385-1396
Low-grade gliomas (LGG) are brain tumors with a low or intermediate biological aggressiveness. According to histopathological features, they are further specified as grade I or II by WHO criteria. Diffuse astrocytomas, oligodendrogliomas, and mixed g
Publikováno v:
Journal of Neurological Surgery Part A: Central European Neurosurgery. 76
BACKGROUND: Intrathecal (IT) drug therapy with implanted pumps is an effective treatment modality for chronic pain and/or spasticity, especially after non-invasive treatment has failed. Long-term use of intrathecal opioids may cause formation of infl
Autor:
Tobias, Kratzsch, Oliver P, Gautschi, Susanne A, Kuhn, Andreas F, Hottinger, Gerhard, Hildebrandt, Martin N, Stienen
Publikováno v:
Praxis. 103(23)
Low-grade gliomas (LGG) are brain tumors with a low or intermediate biological aggressiveness. According to histopathological features, they are further specified as grade I or II by WHO criteria. Diffuse astrocytomas, oligodendrogliomas, and mixed g
Autor:
Susanne Kuhn, Hannes Haberl, Manuela Martin, Tobias Kratzsch, Michael Brodhun, Uwe-Karsten Hanisch
Publikováno v:
Neurological research. 36(8)
Glioblastomas are neuroepithelial tumors with lost cellular differentiation and tenfold increased growth rates compared to low-grade gliomas. Despite of very aggressive treatment options based on surgery, irradiation, and chemotherapy, the prognosis
Autor:
Uwe Karsten Hanisch, Uwe Traeger, Hannes Haberl, Sabine Pfeifenbring, Tobias Kratzsch, Susanne Kuhn, Anne Schirrmeister
Publikováno v:
Journal of Clinical Oncology. 32:e13016-e13016
e13016 Background: Ets-1 regulates migration & angiogenesis and is active in malignomas. Methods: We investigated Ets-1 in 60 glioblastomas WHO IV° & 40 astrocytomas WHO II° and evaluated its progn...
Publikováno v:
Journal of Clinical Oncology. 31:2038-2038
2038 Background: Glioblastoma patients suffer from thromboembolism, aggravating the disease. Recently, increased activity was shown for coagulation factors II, VIII, IX, X, XI, and XII in patient peripheral blood. In vitro, the high potential of FXa-